Behavioral Health Market revenue to surpass USD 67 Billion by 2033, says Research Nester
January 22, 2024 05:00 ET
|
Research Nester
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global behavioral health market size is projected to expand at ~5% CAGR between 2023 and 2033. The market is expected to garner a revenue of USD 67...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09, 2023 09:20 ET
|
Clearmind Medicine Inc.
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada,...
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
May 22, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022 09:00 ET
|
Clearmind Medicine Inc.
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE...
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
December 13, 2022 09:00 ET
|
Clearmind Medicine Inc.
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,CSE:...
Behavioral Health Market to Cross Valuation of US$ 262 Bn by 2031; Growing Need for Treating Substance Abuse Disorders Underpins Abundant Avenues: TMR Study
June 06, 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 06, 2022 (GLOBE NEWSWIRE) -- The global market study on behavioral health market is witnessing steady creation of lucrative opportunities on the back of...
Global Mental Wellness Markets, 2022-2027 - Data Analytics Increasingly Powering Wellness / Use of Technology to Improve Outcomes / Growing Reign of Artificial Intelligence
May 11, 2022 06:48 ET
|
Research and Markets
Dublin, May 11, 2022 (GLOBE NEWSWIRE) -- The "Mental Wellness Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global mental...
Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
October 26, 2021 08:00 ET
|
Clearmind Medicine
TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
October 07, 2021 08:00 ET
|
Clearmind Medicine
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...